Today: 3 June 2026
Why Snail Inc Stock Is Surging Today After ARK Sales Flip Q1 to Profit
14 May 2026
2 mins read

Why Snail Inc Stock Is Surging Today After ARK Sales Flip Q1 to Profit

CULVER CITY, Calif., May 14, 2026, 04:01 PDT

  • Snail Inc. swung to a $2.1 million profit for the first quarter, a turnaround from last year’s $1.9 million net loss, with revenue climbing 35.7% to $27.3 million.
  • SNAL jumped to $1.13 in premarket action at 7:00 a.m. ET, a gain of 125.05% from its last close, per Public.com market data.
  • Snail is up against a June 29 deadline for Nasdaq’s $1 minimum bid rule, making the move part of its ongoing effort to get back into compliance.

Snail Inc. shares shot up over 100% in early premarket hours Thursday, as the video-game publisher returned to profit in the first quarter. The rebound came on the back of increased sales from its ARK franchise as well as the medieval survival game Bellwright.

Timing is key here. According to Snail’s most recent quarterly filing, the company has a deadline of June 29, 2026, to get its share price back above Nasdaq’s $1 minimum and meet the bid price rule. The filing also revealed that on May 11, Snail sent Nasdaq a separate compliance plan—this one addressing requirements around net income, market value, and stockholders’ equity.

Snail shares, which ended Wednesday just under 50 cents, shot higher in premarket trading. That’s more than a blip. A lasting move might take some heat off one listing requirement, though it won’t resolve Nasdaq’s ongoing review of Snail’s full compliance strategy.

Snail’s net revenue climbed to $27.3 million for the quarter ended March 31, up from $20.1 million a year ago. Net income swung to $2.1 million, reversing a loss of $1.9 million in the same period last year. Diluted earnings came in at 5 cents for each Class A share.

The company pointed to ARK: Survival Ascended (ASA) and Bellwright as key drivers behind the revenue increase. ASA contributed a $4.2 million boost, Bellwright chipped in with $2.1 million, and recognized deferred revenue—after fulfilling previous customer commitments—climbed another $2.5 million.

Bookings—a sales metric that excludes deferred revenue impacts—jumped 21.1% to $26.9 million. Unit sales came in 42.6% higher at 2.2 million, according to the filing, helped by an extra 0.5 million ARK franchise units and 0.2 million more Bellwright units moved.

Speaking to investors, CFO Heidy Kingwan Chow said the company started 2026 with “renewed momentum.” She pointed out that first-quarter results picked up on trends seen late last year. During the earnings call, Chow named ASA, Bellwright, and deferred revenue recognition as the primary factors behind the revenue uptick, according to the transcript. The Motley Fool

Snail managed a turnaround in operating leverage. The company’s EBITDA—excluding interest, taxes, and depreciation—came in at $2.4 million, swinging from a $3.2 million loss a year ago. Unrestricted cash climbed as well, hitting $14.3 million, up from $8.6 million at December’s close.

Management’s strategy is tied closely to the upcoming ARK release slate. Snail flagged Fantastic Tames Season 1 for May, while both ARK Tides of Fortune and an ASA remake of Genesis Part 1 are penciled in for June. CEO Hai Shi described the next 12 to 18 months as an “inflection period,” with the company aiming to push further beyond the ARK franchise. GlobeNewswire

The market’s reaction comes down to costs. In April, after Snail renegotiated its ARK license, Noble Capital’s Michael Kupinski bumped his price target to $3.50 from $2.75. The revised deal brought monthly fixed licensing costs down to $1.5 million from $2.0 million—Kupinski figures that’s $1.5 million in quarterly savings.

Snail remains up against stiff competition. In its annual report, the company points to Electronic Arts, Take-Two Interactive, and sandbox-survival studio Facepunch Studios as key rivals. Snail noted that these bigger players often have more money to spend—on development, marketing, and licensing.

Concentration risk is hard to miss. ARK accounted for a hefty 85.7% of Snail’s Q1 revenue, with the top five franchises—ARK among them—responsible for 97.8%. The company flagged potential trouble if new “hit” games get delayed, and pointed to its reliance on third-party platforms like Steam, Xbox, PlayStation, and major app stores. Another warning: slipping out of Nasdaq compliance could pressure both liquidity and the shares.

Latest articles

Archer Aviation trades under $7 as next test looms for air-taxi gamble

Archer Aviation trades under $7 as next test looms for air-taxi gamble

3 June 2026
Archer Aviation shares dipped below $7 premarket after closing at $6.74, as investors weigh heavy cash burn—$217.7 million Q1 net loss, $1.78 billion cash on hand—against hopes for first U.S. eVTOL flights this year; Cantor Fitzgerald cut its price target to $11 but kept an Overweight rating, while 46 disclosed risks and ongoing certification challenges cloud near-term outlook.
Broadcom’s $280 Billion AI Rally Hits Key Test

Broadcom’s $280 Billion AI Rally Hits Key Test

3 June 2026
Broadcom’s stock soared 14% in four days, adding $280 billion in value ahead of Wednesday’s earnings after Alphabet’s $80 billion equity raise spotlighted AI data-center suppliers; with options implying a 9% share move either way, investors await proof that surging AI demand is translating into real revenue growth.
J-Star Stock Moves Up After Texas Battery Update in Pre-Market

J-Star Stock Moves Up After Texas Battery Update in Pre-Market

3 June 2026
J-Star Holding Co. surged to $1.36 in premarket trading after new disclosures on its proposed $122.5 million Baytown, Texas solid-state battery plant, pushing shares above Nasdaq’s $1 minimum less than a week before a key shareholder vote on a reverse split aimed at regaining compliance.
Legend Biotech jumps 42% as traders look at results from small cancer study

Legend Biotech jumps 42% as traders look at results from small cancer study

3 June 2026
Legend Biotech shares soared 42% to $36.28 after early Phase 1 data showed all six higher-dose patients with relapsed or refractory B-cell non-Hodgkin lymphoma responded to its in vivo CAR-T therapy LB2501, with five complete responses; UBS raised its price target to $49, citing the therapy’s outlook, but the results are early and based on a small group with short follow-up.
T1 Energy Stock Falls Premarket After $32M KORE Battery Deal

T1 Energy Stock Falls Premarket After $32M KORE Battery Deal

3 June 2026
T1 Energy shares fell 1.3% premarket after announcing a $32 million KORE Power acquisition to expand into battery storage and AI data-center infrastructure, just a day after a 15.7% stock surge; Northland initiated coverage with an outperform rating and $16 target, but flagged deal execution and funding as key risks.
US Stock Market Today: Dow Futures Rise as Cisco’s AI Surge Tests Wall Street’s Inflation Nerves
Previous Story

US Stock Market Today: Dow Futures Rise as Cisco’s AI Surge Tests Wall Street’s Inflation Nerves

Alphabet’s $60 Billion AI Debt Sprint Puts Google Stock Back in Focus
Next Story

Alphabet’s $60 Billion AI Debt Sprint Puts Google Stock Back in Focus

Go toTop